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Mini Abstract
Tranexamic acid is widely utilized to decrease operative blood loss and blood transfusions.
This prospective randomized trial compares perioperative blood loss in patients undergoing
elective posterior thoracolumbar fusion treated with intravenous versus oral TXA. Not only is
it cheaper, PO was equivalent to IV TXA in reducing blood loss.
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Structured Abstract
Study Design: A prospective randomized trial at a university affiliated tertiary medical
center between February 2017 and March 2020.
Objective: Compare perioperative blood loss in patients undergoing elective posterior
thoracolumbar fusion who were treated with IV versus PO TXA.
Summary of Background Data: The use of antifibrinolytic agents such as tranexamic acid
(TXA) to decrease operative blood loss and allogenic blood transfusions is well documented
in the literature. While evidence supports the use of intravenous (IV) and topical formulations
of TXA in spine surgery, the use of oral (PO) TXA has not been studied.
Methods: 261 patients undergoing thoracolumbar fusion were randomized to receive 1.95g
of PO TXA 2 hours preoperatively or 2g IV TXA (1g before incision and 1g before wound
closure) intraoperatively. The sample was further stratified into 3 categories based on number
of levels fused (1-2 level fusions, 3-5, and >5). The primary outcome was the reduction of
hemoglobin. Secondary outcomes included calculated blood loss, drain output, postoperative
transfusion, complications, and length of hospital stay. Equivalence analysis was performed
with a two one-sided test (TOST).
Results: 137 patients received IV and 124 received PO TXA. The average age was 62±13
years (Mean ± SD), including 141 females and 120 males. Revision cases comprised of 67%
of the total sample. Patient demographic factors were similar between groups except for
weight, BMI, and preoperative platelet count. The mean reduction of hemoglobin was similar
between IV and PO groups (3.56 vs. 3.28 g/dL, respectively; P = 0.002, equivalence). IV
TXA group had a higher transfusion rate compared to PO TXA group (22 patients [19%] vs.
12 patients [10%]; P = 0.03). In addition, IV group had longer length of stay (LOS) than PO
group (4.4 vs. 3.7 days; P = 0.02).
Conclusion: Patients treated with IV and PO TXA experienced the same perioperative blood
loss after small and large spinal fusions. In subgroup analysis, the intermediate (3-5 level)
spinal fusions had less blood loss with PO TXA than IV TXA. Given its lower cost, PO TXA
represents a superior alternative to IV TXA in patients undergoing elective posterior
thoracolumbar fusion and may improve healthcare cost-efficiency in the studied population.
Keywords: tranexamic acid (TXA), spinal fusion, blood loss, allogeneic blood transfusion,
healthcare cost efficiency
Level of Evidence: 1
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Introduction
Intraoperative and postoperative blood loss with elective spinal fusion surgery adversely
affects patient outcomes by increasing coagulopathy, hematoma formation, and anemia1. The
ensuing need for allogenic blood transfusion gives rise to increased risk of infections, longterm mortality, and transfusion reactions, and economic burden2-4. Achieving optimal
perioperative blood conservation, through prophylactic administration of antifibrinolytic
agents, has been the focus in recent years. Specifically, a lysine analoge named tranexamic
acid (TXA) reduces perioperative blood loss and need for blood transfusions in spine surgery
by exerting its anti-fibrinolytic effect through the reversible blockade of lysine binding sites
on plasminogen5-7.
As the utilization of TXA becomes more ubiquitous in spine surgery, the search for the most
efficacious route of TXA administration as well as dosing regimen becomes worthwhile.
TXA can be given intravenously (IV), topically, and orally (PO). Much of the spine literature
focuses on the IV or topical formation8. Potential advantages of the PO formulation include
lower medication cost and ease of administration. There is recent evidence supporting the use
of PO TXA in the adult reconstruction literature9-10, which also showed that PO TXA is more
cost effective than IV TXA. Similarly, our initial phase prospective randomized study
showed equivalent blood loss with IV versus PO TXA11. However, the preliminary data had
insufficient patient numbers to perform subgroup analysis.
Therefore, the objective of this final phase was to compare the efficacy of IV and PO routes
of TXA on perioperative blood loss and allogeneic blood transfusion rate in adult patients
undergoing posterior thoracolumbar instrumented fusion surgery that varied in fusion levels.
Materials and Methods
STUDY DESIGN AND PATIENTS
This study was a single-center, randomized, prospective trial designed to test equivalence
between IV and oral TXA in the setting of elective thoracolumbar fusion between February
2017 and March 2020. Our institutional review board approved the present study, and it was
registered with the public ClinicalTrials.gov registry (NCT03037515). After obtaining
informed consent, adult patients (age>=18 years old) undergoing elective posterior
thoracolumbar instrumented spinal fusions were enrolled in the study. Surgical indications
included spinal stenosis, spondylolysis, spondylolisthesis, degenerative disc disease, adult
spinal deformity, proximal junctional kyphosis, adjacent level disease, and pseudoarthrosis.
Exclusion criteria included known allergy to TXA, history of renal failure or kidney
transplant, history of arterial thromboembolic event (eg. myocardial infarction, stroke) within
the past year, placement of an arterial stent within the past year, a history of thromboembolic
event, coagulopathy, or refusal to receive blood products.
INTERVENTION
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Enrolled patients were randomly assigned between the 2 treatment groups of IV and oral
TXA using a computer-generated random number algorithm. Surgeons and data collectors
were blinded to the patient allocation. Because the number of fusion levels can influence
blood loss, the sample was sub-categorized before randomization by the number of vertebral
levels arthrodesed (1-2 levels, 3-5 levels, >5 levels). Serum and pharmacokinetic studies have
demonstrated that IV TXA reaches therapeutic concentration rapidly but falls below the
threshold after 5 hours; PO TXA reaches therapeutic levels after 2 hours and maintains levels
above the therapeutic threshold for 6 hours after administration11. Based on pharmacokinetic
data, the oral TXA group received 1950 mg TXA (3 tablets of 650 mg) approximately 2
hours before incision. The IV TXA group received the standard dosing for our institution of 1
g TXA (diluted in 100 mL normal saline) given as an IV bolus immediately before incision
and another 1 g TXA given before closure.
SURGICAL TECHNIQUE AND POSTOPERATIVE CARE
Posterior instrumented spinal fusions were performed prone on a Jackson table with the
abdomen free. A forced-air warming device was used to maintain normothermia. A standard
open midline approach was utilized, intertransverse fusion beds were prepared uniformly, and
pedicle screws were inserted in the standard fashion. When indicated, transforaminal lumbar
(TLIF) and direct lateral interbody (DLIF) fusions were also performed per surgeon
preference. Before wound closure, hemostasis was achieved and drains were placed routinely.
All cases were performed by surgeons with over 25 years experience in spine surgery.
BLOOD MANAGEMENT
An autologous blood recovery system (Cell Saver, Haemonetics, MA) was used when
requested by the surgeon and salvaged red blood cells (RBCs) were returned to the patient.
Suctioned blood from the surgical field was processed and given back to the patient if
estimated blood loss (EBL) was greater than 500 mL or at the surgeon’s discretion. As a
result, not every patient may have been given salvaged RBCs. Intraoperative blood
transfusion was given if hemoglobin (Hgb) dropped below 7.0 g/dL or at the
anesthesiologist’s discretion, such as if patient was unstable despite fluid resuscitation and
salvaged RBC replacement. The postoperative transfusion protocol required transfusion for a
Hgb level below 7.0 g/dL or if Hgb was between 7.0 and 8.0 g/dL and patients had
symptomatic anemia including tachycardia, hypotension, or pallor.
DATA COLLECTION
Patient demographic and preoperative characteristics were documented for comparison
between the treatment groups. All patients had postoperative labs including a complete blood
count (CBC) nightly starting on Post-operative Day 0 (POD0) until drains were removed.
Drain outputs were recorded three times a day (per 8 hour shift). Drains were discontinued if
output was below 30 mL per shift or by the end of postoperative day 2. The recorded
characteristics included the following: age, sex, American Society of Anesthesiologists'
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physical status classification (ASA), weight, height, body mass index (BMI), and pertinent
preoperative laboratory values (prothrombin time/international normalized ratio, creatinine,
platelet count, hematocrit, and hemoglobin).
OUTCOME MEASURES
The primary outcome was reduction of Hgb, which was the difference between preoperative
and the lowest postoperative Hgb values during the inpatient admission. Secondary outcomes
included calculated blood loss, reduction of hematocrit, drain output, rate of postoperative
transfusion, thromboembolic event, infections and length of hospital stay. In addition,
intraoperative measures such as case length, calculated blood loss, intravenous fluid received
and number receiving intraoperative cell saver and blood transfusion were investigated.
Blood loss was calculated as a function of patient characteristics including sex, weight, and
height as well as preoperative and postoperative hemoglobin balance12-13.
SAMPLE SIZE AND STATISTICAL ANALYSIS
A pretest power analysis determined that 30 patients in each group were needed to show a 1.0
g/dL difference in hemoglobin drop, assuming an equivalence margin of ±1.0 g/dL, 5% alpha
error, and 80% power. The primary outcome of Hgb drop and the secondary outcome of
calculated blood loss were tested for equivalence using a two one-sided test (TOST). The
remaining secondary outcomes and covariates were compared using traditional t-tests.
Ordinal scale outcome variables were tested using nonparametric methods such as chi-square
or Fisher exact test. A P-value of <0.05 suggests statistical significance. All data were
analyzed by Microsoft Excel 2011 (Microsoft, Seattle, WA) and XLSTAT 2017: Data
Analysis and Statistical Solution for Microsoft Excel (Addinsoft, Paris, France).
Results
During the period of study enrollment from February 2017 and March 2020, 300 patients
were scheduled for elective thoracolumbar fusion surgery, which included spinal stenosis,
spondylolysis, spondylolisthesis, degenerative disc disease, adult spinal deformity, proximal
junctional kyphosis, adjacent level disease, and pseudoarthrosis. 39 patients were ineligible
due to meeting exclusion criteria, refusal to participate or missing pertinent lab values (Figure
1). Among the 261 enrolled study participants who underwent randomization, 137 had IV
TXA and 124 had PO TXA. No patient was lost or excluded during the follow-up period.
Two orthopaedic spine surgeons performed the operations: GG performed majority of the
surgeries (97% of total, 98% and 95% for IV and PO, respectively), and SB performed the
rest. Standard posterior approach was utilized in all cases except for one DLIF that was
performed in the PO group.
The average age of enrolled patients was 62±13 years (Mean ± SD). There were 141 females
and 120 males. There were no statistical differences in the patient characteristics and
preoperative measurements pertaining to age, sex, height, ASA, estimated blood volume,
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preoperative anticoagulant use, and pertinent preoperative laboratory values including
hemoglobin, hematocrit, INR, and creatinine (Table 1). Weight was higher in PO TXA group,
so BMI was higher in the PO group (32.0±5.8 kg/m2) than in the IV TXA group (29.5±5.9
kg/m2) (P = 0.0006). Furthermore, preoperative platelet count was higher in PO group
(246±70 x103/mm3) than in IV group (224±77 x103/mm3) (P = 0.02). Revision cases
comprised of 67% of the total sample (66% and 67% for IV and PO, respectively). A single
level pedicle subtraction osteotomy (PSO) was performed for 18 patients (12 and 6 for IV
and PO, respectively) by GG. TLIF was performed for 22 patients (11 and 19 for IV and PO,
respectively). Intraoperative measures between the treatment groups demonstrated no
statistical difference in anesthesia time, surgery time, IVF, percentage of patients receiving
cell saver, and percentage of patients receiving blood transfusion. Overall, the patients within
the two treatment groups were considered similar in regard to the measured independent
variables (Table 2).
PRIMARY OUTCOME MEASURE
The reduction in Hgb was statistically equivalent between IV and PO TXA (Table 3). The
reduction in hemoglobin for the IV TXA group was 3.56±1.93 g/dL while the drop in Hgb for
the PO TXA group was 3.28±1.60 g/dL (P = 0.002, equivalent).
SECONDARY OUTCOME MEASURES
The calculated blood loss between the IV and PO TXA groups was equivalent (Table 3). On
average, the volume of blood loss for the IV and PO TXA groups was 1270±677 mL and
1219±610 mL (P = 0.001, equivalent), respectively. Hematocrit drop between IV and PO
TXA groups was also equivalent (Table 3). The change in hematocrit for IV and PO groups
was calculated to be 10.5±5.8% and 9.9±5.4% (P < 0.001, equivalent), respectively.
Postoperative rate of transfusion, drain output, length of hospital stay, and complications
demonstrated no statistical difference between IV and PO TXA groups (Table 3). Total drain
output for IV and PO TXA groups was similar at 676±452 mL and 651±469 mL (P = 0.41),
respectively. IV TXA group had a higher postoperative transfusion rate compared to PO TXA
group (22 patients [19%] vs. 12 patients [10%]; P = 0.03). Three patients (2%) in each group
experienced a DVT/PE (P = 0.90). Eight patients in IV TXA group (6%) and 5 patients in PO
TXA group (4%) had surgical site infections (P = 0.50). Length of hospital stay was longer in
IV group compared to PO group, 4.4±2.8 days and 3.7±2.4 days (P = 0.02), respectively.
SUBGROUP ANALYSIS
The total sample was sub-categorized by the number of vertebral levels arthrodesed (1-2
levels, 3-5 levels, >5 levels). The sample size was big enough in each subgroup to allow
independent statistical analysis (Table 4a-c). The 1-2 level fusion group and the >5 level
fusion group demonstrated that IV TXA was equivalent to PO TXA (Hgb drop: 2.34±1.35 vs.
2.73±1.32 g/dL [P < 0.01] and 4.97±1.65 vs. 4.79±1.65 g/dL [P = 0.03], respectively;
equivalence). However, the 3-5 level fusion group showed that IV TXA had higher
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hemoglobin drop compared to PO (4.22±1.54 vs. 3.04±1.22 g/dL; P < 0.001). The secondary
outcomes of calculated blood loss and change in hematocrit showed similar trends (Table 4ac). Additionally, body mass index, revision, interbody fusion, osteotomy, anticoagulant use,
anesthesia and surgical time can all affect blood loss (Table 5a-c). In the 1-2 level fusion
group and the >5 level fusion group, BMI was higher in PO than IV TXA (32.6±5.6 vs.
29.4±6.3 kg/m2 [P < 0.005] and 32.1±6.9 vs. 28.2±5.2 kg/m2 [P = 0.01], respectively). In the
3-5 level fusion group, number (%) of anticoagulant use was higher in IV vs. PO TXA (14%
vs 0; P = 0.03) and anesthesia time was higher in IV vs. PO TXA (372±71 vs. 340±60 min; P
= 0.04).
Discussion
Spinal fusion surgery has been associated with significant perioperative blood loss, which
leads to elevated transfusion rates and serious complications14-15. Greater healthcare costs
result from cost of blood products, increased hospital stay and complications4. Tranexamic
acid has been studied and utilized as a hemostatic agent since the 1960s, and its use in spine
surgery ranges from pediatric to adults, from routine degenerative cases to complex
deformity cases. A plethora of studies has demonstrated TXA’s effects in reducing blood loss
and transfusion rates5. While most studies focused on the intravenous and topical forms of
TXA8,16, this is one of the first studies in the spine literature that compares IV versus PO
formulations of TXA. We found no difference in the efficacy between the two routes of
administration in both the primary outcome of hemoglobin drop and secondary outcomes. PO
TXA appears to be as safe as IV TXA in regards to postoperative thromboembolic events and
infections. Furthermore, PO TXA was associated with lower transfusion rate compared to IV
group.
Compared to total joints literature, where all formulations of TXA have been shown to be
effective9,17-18, the spine literature has been limited to the IV route of administration. Spine
surgeons preferred to use IV TXA, especially in larger cases due to larger exposures and
more extensive dissection. In both the small (1-2 level) and large (>5 level) fusion subgroups,
BMI was higher in the PO TXA treatment group. Previous studies indicated that higher BMI
was associated with increased blood loss19-20, but our sub-analysis showed that PO and IV
TXA had similar blood loss for the small and large fusion subgroups, which provided further
evidence that PO TXA is effective at reducing blood loss. On the other hand, PO TXA was
more effective than IV TXA at reducing blood loss in 3-5 level fusions. In this subgroup, IV
TXA group had more anticoagulant use compared to PO TXA group (14% vs. 0%, P = 0.03).
Also, surgery was longer in IV group compared to PO group (372±71 vs. 340±60 min, P =
0.04). Similarly, Peters el al. showed that IV TXA became increasingly effective with higher
fused levels and longer surgical time21. Although anticoagulants were stopped according to
protocol in all of our patients, their systemic clearance cannot be accurately predicted in the
patients.
Given the ever-changing landscape of medical reimbursement, cost effective health care
practice is beneficial to patients, providers, the healthcare system and society at large. The
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use of TXA in orthopaedic surgery has become a routine practice because it has been shown
to be safe, clinically beneficial, and cost effective22. TXA offers not only direct savings from
transfusion costs23 but also inpatient hospital cost that is related to length of stay24. Given that
PO TXA is cheaper and easier to administer than IV TXA, switching to PO can lead to
greater cost savings. In our institution, the oral TXA dosage cost $14 compared with $53 for
the generic IV formulation alone (not including the cost of pharmacy preparation). Reducing
length of stay with PO TXA can generate even greater cost savings. As the American
population continues to age, the number of spinal fusion surgeries performed in the United
States will likely continue to increase from the current annual rate of about 500,000.
Consequently, transitioning to PO TXA has potential to yield cost savings of at least 20
million dollars per year for the health care system.
Our study is not without potential limitations. First, the study population contains
heterogeneity such as varying patient diagnosis and surgical technique/approach. However,
heterogeneity was minimized through sub-stratification of the number of fusion levels into
three categories. Posterior approach was mostly used (100% and 99% for IV and PO,
respectively), and a single surgeon performed most of the cases (98% and 95% for IV and
PO, respectively). Second, blood loss calculation was based on the lowest postoperative
hemoglobin value, which may be inaccurate due to hemodilution if the patient was
discharged before postoperative day five18. However, change in hematocrit was similar for IV
and PO groups. Despite these limitations, the validity of our results should be maintained, as
the same methodology was applied to both treatment arms.
The third potential limitation is that we did not include a placebo group and assumed that PO
TXA was superior to placebo based on current literature. We believe that using the standard
IV formulation as a control instead of a pure placebo was more clinically useful.
Additionally, because perioperative bleeding during spine surgery is multifactorial and can be
more significant than TKA or THA25, we would put patients at increased risk for blood loss if
we did not give TXA. Additionally, administration of TXA in spine surgery is already
emerging as the standard of care, and this study is an attempt to optimize current standards.
Lastly, the large percentage (67%) of revision cases in our cohort is a limitation as the results
are not directly generalizable to primary cases. Strengths of this study include that it was
completed at a single center and by a single surgeon predominantly.
Conclusion
In conclusion, in the setting of spine thoracolumbar fusions, oral tranexamic acid produced an
equivalent reduction in hemoglobin and blood loss compared to its intravenous counterpart.
Given the equivalent clinical outcomes, potential hospital cost savings, and the ease of drug
administration, oral tranexamic acid is a superior alternative to intravenous tranexamic acid.
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Key Points




The mean reduction of hemoglobin and calculated blood loss were equivalent
between IV and PO TXA groups.
Postoperative complication rates were similar between the two groups, but transfusion
rate was higher in IV TXA group. Length of stay was longer in IV TXA group.
PO TXA is a superior alternative to IV TXA in patients undergoing elective posterior
thoracolumbar fusion.
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Figure 1. CONSORT (Consolidated Standards of Reporting Trials) flow diagram of the
study. TXA, tranexamic acid.
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Table 1. Patient characteristics
IV

PO

137

124

64 (12)

61 (13)

0.07

64/73

56/68

0.80a

Weight (kg)

85 (20)

92 (21)

0.005

Height (m)

1.69 (0.11)

1.69 (0.11)

0.9

Body mass index

29.5 (5.9)

32.0 (5.8)

0.0006

Estimated blood volume (mL)

4916 (972)

5144 (1050)

0.07

2.7 (0.5)

2.7 (0.5)

0.85

Class I (n)

0

2

Class II (n)

40

31

Class III (n)

93

90

Class IV (n)

4

1

4.0 (2.8)

3.7 (2.8)

1-2 levels

57

62

3-5 levels

44

34

>5 levels

36

28

Number (%) of revisions

91 (66%)

83 (67%)

0.93a

Number (%) of interbody fusions

11 (8%)

19 (15%)

0.07a

Number (%) of osteotomies

19 (14%)

14 (11%)

0.53a

Number (%) of anticoagulant use

12 (9%)

6 (5%)

0.21a

Preoperative Hgb (g/dL)

13.4 (1.5)

13.6 (1.7)

0.34

Preoperative Hct (%)

40.0 (4.4)

40.5 (4.6)

0.34

Preoperative platelet count (x103/mm3)

224 (77)

246 (70)

0.02

Preoperative INR

1.07 (0.12)

1.05 (0.16)

0.26

Preoperative creatinine (mg/dL)

0.97 (0.71)

0.92 (0.74)

0.6

Number of patients
Mean age (yr)
Sex (M/F)

ASA

Number of fused levels

P*

0.38

Mean (SD)
*Statistical analysis for comparison between groups: P < 0.05, statistical significance.
a 2

x test or Fisher exact test.

Table 2. Intraoperative measures
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IV (N=137)

PO (N=124)

P*

Anesthesia time (min)

372 (104)

356 (98)

0.2

Surgical time (min)

275 (101)

266 (97)

0.45

3402 (1759)

3365 (1449)

0.85

54 (39%)

42 (34%)

0.35a

9 (7%)

3 (2%)

0.11a

Intravenous fluid (mL)
Number (%) receiving cell saver
Number (%) receiving blood transfusion
Mean (SD)

*Statistical analysis for comparison between groups: P < 0.05, statistical significance.
a 2

x test or Fisher exact test.

Table 3. Outcome measurements
IV (N=137)

PO (N=124)

P*

Hgb drop (g/dL)

3.56 (1.93)

3.28 (1.60)

0.002c

Calculated blood loss (mL)

1270 (677)

1219 (610)

0.001c

Hct drop (%)

10.5 (5.8)

9.9 (5.4)

<0.0001c

Drain output (mL)

676 (452)

651 (469)

0.41

Number (%) postop transfusion

26 (19%)

12 (10%)

0.03a

Number (%) DVT/PE

3 (2%)

3 (2%)

0.90a

Number (%) infections

8 (6%)

5 (4%)

0.50a

4.4 (2.8)

3.7 (2.4)

0.02

Length of hospital stay (days)
Mean (SD)

*Statistical analysis for comparison between groups: P < 0.05, statistical significance.
a 2

x test or Fisher exact test.

c

Welch two one-sided test: P < 0.05 demonstrates equivalence between treatments.
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Table 4a. Outcome measurements for 1-2 fused levels
IV (N=57)

PO (N=62)

Pc

Hgb drop (g/dL)

2.34 (1.35)

2.73 (1.32)

<0.01

Calculated blood loss (mL)

850 (436)

1020 (514)

0.01

Hct drop (%)

6.6 (3.6)

8.1 (4.0)

0.02

Mean (SD)
c

Welch two one-sided test: P < 0.05 demonstrates equivalence between treatments.

Table 4b. Outcome measurements for 3-5 fused levels
IV (N=44)

PO (N=34)

P*

Hgb drop (g/dL)

4.22 (1.54)

3.04 (1.22)

<0.001

Calculated blood loss (mL)

1559 (582)

1115 (444)

<0.001

Hct drop (%)

12.7 (4.6)

9.2 (3.7)

<0.001

Mean (SD)
*Statistical analysis for comparison between groups: P < 0.05, statistical significance.
Table 4c. Outcome measurements for >5 fused levels
IV (N=36)

PO (N=28)

Pc

Hgb drop (g/dL)

4.97 (1.65)

4.79 (1.65)

0.03

Calculated blood loss (mL)

1706 (612)

1783 (651)

0.03

Hct drop (%)

14.7 (5.0)

14.7 (7.0)

0.04

Mean (SD)
c

Welch two one-sided test: P < 0.05 demonstrates equivalence between treatments.
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Table 5a. Baseline characteristics for 1-2 fused levels
IV (N=57)

PO (N=62)

P*

BMI (kg/m )

29.4 (6.3)

32.6 (5.6)

<0.005

Number (%) of revisions

38 (67%)

36 (58%)

0.33a

5 (9%)

11 (18%)

0.15a

0

0

N/A

4 (7%)

4 (6%)

0.9a

Anesthesia time (min)

302 (55)

303 (49)

0.97

Surgical time (min)

206 (50)

211 (47)

0.58

IV (N=44)

PO (N=34)

P*

BMI (kg/m2)

30.6 (6.0)

30.9 (5.4)

0.84

Number (%) of revisions

27 (61%)

22 (65%)

0.76a

Number (%) of interbody fusions

3 (7%)

6 (18%)

0.14a

Number (%) of osteotomies

1 (2%)

2 (6%)

0.41a

Number (%) of anticoagulant use

6 (14%)

0

0.03a

Anesthesia time (min)

372 (71)

340 (60)

0.04

Surgical time (min)

272 (67)

253 (60)

0.18

IV (N=36)

PO (N=28)

P*

BMI (kg/m )

28.2 (5.2)

32.1 (6.9)

0.01

Number (%) of revisions

26 (72%)

25 (89%)

0.09a

3 (8%)

2 (7%)

0.86a

18 (50%)

12 (43%)

0.57a

2 (6%)

2 (7%)

0.79a

Anesthesia time (min)

482 (102)

493 (88)

0.67

Surgical time (min)

387 (99)

402 (86)

0.52

2

Number (%) of interbody fusions
Number (%) of osteotomies
Number (%) of anticoagulant use

Mean (SD)
*Statistical analysis for comparison between groups: P < 0.05, statistical significance.
a 2

x test or Fisher exact test.

Table 5b. Baseline characteristics for 3-5 fused levels

Mean (SD)
*Statistical analysis for comparison between groups: P < 0.05, statistical significance.
a 2

x test or Fisher exact test.

Table 5c. Baseline characteristics for >5 fused levels

2

Number (%) of interbody fusions
Number (%) of osteotomies
Number (%) of anticoagulant use

Mean (SD)
*Statistical analysis for comparison between groups: P < 0.05, statistical significance.
a 2

x test or Fisher exact test.

Copyright © 2021 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

